CMPX Stock Forecast: Compass Therapeutics, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Compass Therapeutics, Inc. is $4. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 29 of 100 as at 18 Nov 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Compass Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (81): Reported profit is backed by cash, and the company is not expanding recklessly.
Momentum (7): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
CMPX stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on CMPX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
Of the 20 most recent actions, 1 moved their price target up and 7 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 10 Nov 2026 | Wedbush | Maintains | Neutral | $1.00 → $0.90 |
| 23 Sept 2026 | Citizens | Maintains | Market Outperform | $10 → $4.00 |
| 23 Sept 2026 | Craig-Hallum | Maintains | Buy | $15 → $8.00 |
| 23 Sept 2026 | Guggenheim | Maintains | Buy | $8.00 → $4.00 |
| 23 Sept 2026 | HC Wainwright & Co. | Maintains | Buy | $24 → $12 |
| 23 Sept 2026 | Wedbush | Downgrade | Neutral | $5.00 → $1.00 |
| 7 Aug 2026 | Piper Sandler | Maintains | Overweight | $4.00 → $6.00 |
| 28 Apr 2026 | Canaccord Genuity | Maintains | Buy | $13 → $7.00 |
| 28 Apr 2026 | Citizens | Reiterates | Market Outperform | $10 |
| 27 Apr 2026 | D. Boral Capital | Maintains | Buy | $30 |
| 27 Apr 2026 | HC Wainwright & Co. | Reiterates | Buy | $24 |
| 24 Mar 2026 | Guggenheim | Reiterates | Buy | — |
| 6 Jan 2026 | D. Boral Capital | Maintains | Buy | — |
| 5 Jan 2026 | William Blair | Initiates | Outperform | — |
| 3 Dec 2025 | Canaccord Genuity | Initiates | Buy | — |
| 3 Dec 2025 | Cantor Fitzgerald | Initiates | Overweight | — |
| 3 Dec 2025 | Citizens | Initiates | Market Outperform | — |
| 5 Nov 2025 | D. Boral Capital | Maintains | Buy | — |
| 6 Oct 2025 | LifeSci Capital | Initiates | Outperform | — |
| 12 Aug 2025 | D. Boral Capital | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for CMPX.
This page is one stock. Monday covers all of them.
CMPX appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
CMPX vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 19 Nov 2026, Compass Therapeutics, Inc. returned −86.2% against +9.2% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
CMPX analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 0.9×
- EV / EBITDA
- —
Cheaper than 77% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −49.0%
- Return on assets
- −29.0%
- Dividend yield
- —
Higher than 22% of US stocks
Higher than 15% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Compass Therapeutics, Inc. has a market value of $122.2M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$73.4M.
Diluted earnings per share, trailing twelve months: −$0.40.
Free cash flow in the twelve months to 30 June 2026: −$56.4M.
Compass Therapeutics, Inc. employs 39 people.
Data provided by Twelve Data
CMPX and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at CMPX’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Compass Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about CMPX
What is the CMPX stock price forecast for 2026-2027?
The median 12-month analyst price target for Compass Therapeutics, Inc. is $4, with estimates ranging from $0.9 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is CMPX stock a buy right now?
Of the 15 analysts covering Compass Therapeutics, Inc., 12 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Compass Therapeutics, Inc. 29 out of 100 across roughly 4,300 US stocks as at 18 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank CMPX?
As at 18 Nov 2026, Compass Therapeutics, Inc. ranks 29 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (81 of 100).
Will CMPX stock go up?
No one can know that. What the data says: the median 12-month target from 15 analysts is $4, and Ticker Nerd's factor model ranks Compass Therapeutics, Inc. 29 out of 100 as at 18 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the CMPX stock forecast for 2030?
No analyst covering Compass Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CMPX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $0.9 to $12 over the next 12 months.
How has CMPX stock performed over the past year?
Compass Therapeutics, Inc. returned -86.2% over the 12 months to 19 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Compass Therapeutics, Inc. do?
Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapies for cancer. The company concentrates on oncology programs that target angiogenesis, immune activation, and tumor-driven immunosuppression, with product candidates designed to address critical biological pathways involved in anti-tumor responses.
About Compass Therapeutics, Inc.
Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapies for cancer. The company concentrates on oncology programs that target angiogenesis, immune activation, and tumor-driven immunosuppression, with product candidates designed to address critical biological pathways involved in anti-tumor responses. Its current pipeline includes bispecific and monoclonal antibody programs such as tovecimig, CTX-471, CTX-8371, and CTX-10726, reflecting a platform built around antibody discovery and engineering. Compass Therapeutics uses proprietary technologies to identify and optimize therapeutic leads and to create modular, manufacturable bispecific candidates. The company plays a specialized role in the biotechnology market by advancing immuno-oncology research into clinical development, with a focus on solid tumors and other cancer indications.
CEO Dr. Thomas J. Schuetz M.D., Ph.D. · 39 employees · United States · https://www.compasstherapeutics.com